Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
The development of a single immuno-metabolic adjuvant capable of modulating, in the appropriate direction and intensity, the complex antagonistic and symbiotic interplays between tumor cells, immune cells, and the gut microbiota may appear pharmacologically implausible. Metformin might help solve th...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:10256/18299 |
| Acceso en línea: | http://hdl.handle.net/10256/18299 |
| Access Level: | acceso abierto |
| Palabra clave: | Metformina Metformin Adjuvants immunològics Immunological adjuvants Càncer -- Immunoteràpia Cancer -- Immunotherapy Càncer -- Tractament Cancer -- Treatment |
| Sumario: | The development of a single immuno-metabolic adjuvant capable of modulating, in the appropriate direction and intensity, the complex antagonistic and symbiotic interplays between tumor cells, immune cells, and the gut microbiota may appear pharmacologically implausible. Metformin might help solve this conundrum and beneficially impact the state of cancer-immune system interactions |
|---|